Table 2.
Results of randomized, placebo-controlled trials of oral pentavalent human-bovine (WC3) reassortant rotavirus vaccine in middle-upper versus lower income countries (adapted from [10]).
| location | age of vaccinees | no. doses | titre (pfu)a | follow-up | PEb (95% CI)* (%) | severity classification |
|---|---|---|---|---|---|---|
| mid-upper | ||||||
| US | 2–6 months | 3 | 107 | 1 year | 100 (44,100) | Clark ≥17 |
| US, Finland | 2–6 months | 3 | 107 | 2 years | 98 (88,100) | Vesikari ≥11 |
| US, Finland, Latin America | 2–8 months | 3 | 107.3 | 1 year | 94 (91,97) | hospitalization ED visits |
| lower | ||||||
| Ghana, Kenya, Mali | 4–21weeks | 3 | 2 × 107 | 2 years | 39 (19,55) | Vesikari ≥11 |
| Bangladesh, Vietnam | 4–26 weeks | 3 | 2 × 107 | 2 years | 48 (22,66) | Vesikari ≥11 |
*p < 0.001for interaction of PE between middle-upper versus lower income countries.
aPlaque-forming units.
bProtective efficacy.